No Efficacy Data Yet; Preparing Proposal to Inoculate Children Between 2 & 16 Years: Bharat Biotech Chairman
FOLLOW US ON:
As the country readies itself for the long-awaited COVID-19 vaccination drive beginning Saturday, Bharat Biotech Chairman Dr Krishna Ella said India can expect interim efficacy data on its vaccine once the trials are over. He also added that Bharat Biotech is preparing a proposal to start trials in children aged between 2 and 16.
In an interview to CNN-News18 s Sneha Mordani, Bharat Biotech Managing Director Dr Krishna Ella and co-founder and Joint Managing Director Suchitra Ella talked of the efficacy data, Covaxin s availability in the market and its effectiveness against the new coronavirus variant.
Adar Poonawala
India is all set to receive the 1st Covid-19 vaccine as the Drug Controller General of India (DCGI) on Sunday has approved Oxford AstraZeneca’s CoviShield and Bharat Biotech’s Covaxin for restricted use in India. India is gearing up to begin the biggest vaccination drive for one nation in history. However, controversy has arisen over the name of the Pune-based Serum Institue of India’s vaccine. A civil court in Pune issued a notice to SII on the application of a pharmaceutical company and vendor.
This vaccine, prepared by Oxford University, has been named ‘Covishield’ but at the same time, Adar Poonawala’s company has received notice regarding the name of the vaccine. The notice requested the Serum Institute of India to stop using ‘Covishield’ trademarks or other similar names in its upcoming covid-19 vaccination. This has been filed by Maharashtra’s Nanded-based firm, Cutis-Biotech claiming that they had been using the ‘Kovishield’ trademark s